Cognitive EnhancementNCT06689644
Effect of a Plant Based Nootropic on Perceptual Decision Making.
A study testing Nootropics (ginkgo biloba, nicergoline, piracetam, or others), Perceptual decision-making performance and Electroencephalography in people with Cognitive Enhancement, run by University of Leeds at 1 site in United Kingdom.
Trial summary
Nootropics are a group of medicinal substances purported to improve important cognitive functions such as learning, focus and memory. Many of these substances have demonstrated beneficial effects on cognitive performance and overall health. Read more about this study
- Who is it for?
- Ages 20 to 59 yearsHealthy volunteers can take part
- Conditions the study is for
- Cognitive Enhancement
- What is being tested?
- Nootropics (ginkgo biloba, nicergoline, piracetam, or others), Perceptual decision-making performance and Electroencephalography
- Type of treatment
- Medical device, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 37 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 23 Oct 2023to 1 Jun 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 59 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Eligibility screening of participants was guided by the following inclusion criteria: (i) be between 20-59 years old, (ii) be right-handed and (iii) be able to cease taking other dietary supplements for two months.
Who cannot join
- Exclusion criteria included: (i) currently consuming a nootropic supplement, (ii) any known musculoskeletal, or neurological medical conditions or cognitive impairments (iii) have a known diagnosis of epilepsy/history of seizures and (iv) have a known hearing or visual condition that affects daily life function.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of a Plant-based Nootropic Supplement on Perceptual Decision-making and Brain Network Interdependencies: a Randomised, Double-blinded and Placebo-controlled Study.
Nootropics are a group of medicinal substances purported to improve important cognitive functions such as learning, focus and memory. Many of these substances have demonstrated beneficial effects on cognitive performance and overall health. However, a thorough understanding of how these substances and their synergistic effects in the form of a supplement may benefit fundamental brain processes is currently lacking. In the current study, we will investigate the effects of a plant-based, nootropic supplement (https://uk.mindlabpro.com/) on perceptual decision-making (i.e. the ability to make rapid decisions based on sensory stimuli) in healthy adult participants.
Read the detailed description
Participants will perform a computerised cognitive task assessing their perceptual decision-making pre- and post- 60 days of continuous supplementation with either a plant-based nootropic supplement (Mind Lab pro) or placebo. During testing, electroencephalography (EEG) signals will be captured simultaneously.
- Conditions
- Cognitive Enhancement
- Being tested
- Nootropics (ginkgo biloba, nicergoline, piracetam, or others), Placebo, Perceptual decision-making performance, Electroencephalography
- Keywords
- Perceptual decision-making, Cognitive enhancement, Nootropics, EEG, Brain health
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nootropics (ginkgo biloba, nicergoline, piracetam, or others)Dietary supplement
Commercially available product: Mind lab pro
PlaceboDietary supplement
A cellulose commonly used as a bulking agent in supplement products
Perceptual decision-making performanceBehavioural
A computerised cognitive task involving rapid visual categorisation of images
ElectroencephalographyDevice
Brain signals are recorded from a 64 channel EEG system during the cognitive task
| Study group | Role | What they receive |
|---|---|---|
| Experimental group | Experimental | This group will receive the nootropic supplement for 60 days. Receives: Dietary Supplement: Nootropics (ginkgo biloba, nicergoline, piracetam, or others); Behavioral: Perceptual decision-making performance; Device: Electroencephalography |
| Control group | Placebo comparator | This group will receive a placebo supplement for 60 days Receives: Dietary Supplement: Placebo; Behavioral: Perceptual decision-making performance; Device: Electroencephalography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Perceptual decision-making performance
Choice accuracy and reaction times
Measured: Pre- and post- 60 days of supplementation
Secondary outcomes (1)
Brain network interdependencies
Patterns extracted from brain signals using electroencephalography
Measured: Pre- and post- 60 days of supplementation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2024
- Study start23 Oct 2023
- Primary completion6 Mar 2024
- Study completion1 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Cognitive EnhancementStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 37 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Leeds
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr Andrea Utley, University of Leeds
- Investigators
- Ioannis Delis, Principal investigator, University of Leeds
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06689644
- Sponsor's protocol ID
- AUtley
- Status last verified
- Nov 2024
- First submitted
- 13 Nov 2024
- Last updated
- 14 Nov 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: No further investigations will take place using this data with anyone outside of the current research group
Publications
O'Reilly D, Bolam J, Delis I, Utley A. Effect of a Plant-Based Nootropic Supplement on Perceptual Decision-Making and Brain Network Interdependencies: A Randomised, Double-Blinded, and Placebo-Controlled Study. Brain Sci. 2025 Feb 21;15(3):226. doi: 10.3390/brainsci15030226.
PubMed 40149748
Study at a glance
From the registry record, last updated by the sponsor on 14 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of a Plant-based Nootropic Supplement on Perceptual Decision-making and Brain Network Interdependencies: a Randomised, Double-blinded and Placebo-controlled Study.
- ClinicalTrials.gov ID
- NCT06689644
- Acronym / sponsor ID
- AUtley
- Conditions
- Cognitive Enhancement
- Keywords
- Perceptual decision-making, Cognitive enhancement, Nootropics, EEG, Brain health
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 37 participants (actual)
- Lead sponsor
- University of LeedsUniversity, hospital or other
- Study start
- 23 Oct 2023 (actual)
- Primary completion
- 6 Mar 2024 (actual)
- Study completion
- 1 Jun 2024 (actual)
- First posted
- 14 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Nootropics are a group of medicinal substances purported to improve important cognitive functions such as learning, focus and memory. Many of these substances have demonstrated beneficial effects on cognitive performance and overall health. However, a thorough understanding of how these substances and their synergistic effects in the form of a supplement may benefit fundamental brain processes is currently lacking. In the current study, we will investigate the effects of a plant-based, nootropic supplement (https://uk.mindlabpro.com/) on perceptual decision-making (i.e. the ability to make rapid decisions based on sensory stimuli) in healthy adult participants.
Detailed description
Participants will perform a computerised cognitive task assessing their perceptual decision-making pre- and post- 60 days of continuous supplementation with either a plant-based nootropic supplement (Mind Lab pro) or placebo. During testing, electroencephalography (EEG) signals will be captured simultaneously.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental group | Experimental | Dietary Supplement: Nootropics (ginkgo biloba, nicergoline, piracetam, or others), Behavioral: Perceptual decision-making performance, Device: ElectroencephalographyThis group will receive the nootropic supplement for 60 days. |
| Control group | Placebo comparator | Dietary Supplement: Placebo, Behavioral: Perceptual decision-making performance, Device: ElectroencephalographyThis group will receive a placebo supplement for 60 days |
Who may qualify
- Ages
- 20 to 59 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- Eligibility screening of participants was guided by the following inclusion criteria: (i) be between 20-59 years old, (ii) be right-handed and (iii) be able to cease taking other dietary supplements for two months.
Key exclusion criteria (1 listed)
- Exclusion criteria included: (i) currently consuming a nootropic supplement, (ii) any known musculoskeletal, or neurological medical conditions or cognitive impairments (iii) have a known diagnosis of epilepsy/history of seizures and (iv) have a known hearing or visual condition that affects daily life function.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nootropics (ginkgo biloba, nicergoline, piracetam, or others)Commercially available product: Mind lab pro | Dietary supplement | Experimental group |
| PlaceboA cellulose commonly used as a bulking agent in supplement products | Dietary supplement | Control group |
| Perceptual decision-making performanceA computerised cognitive task involving rapid visual categorisation of images | Behavioural | Control group, Experimental group |
| ElectroencephalographyBrain signals are recorded from a 64 channel EEG system during the cognitive task | Device | Control group, Experimental group |
Primary outcome
Perceptual decision-making performance
Time frame: Pre- and post- 60 days of supplementation
Choice accuracy and reaction times
1 secondary outcome
Brain network interdependencies
Time frame: Pre- and post- 60 days of supplementation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Nov 2024.
- Derived from this study: PubMed 40149748O'Reilly D, Bolam J, Delis I, Utley A. Effect of a Plant-Based Nootropic Supplement on Perceptual Decision-Making and Brain Network Interdependencies: A Randomised, Double-Blinded, and Placebo-Controlled Study. Brain Sci. 2025 Feb 21;15(3):226. doi: 10.3390/brainsci15030226.
- Pre-registration of the studyLink provided by the sponsor.
- Individual participant dataSharing planned: No. No further investigations will take place using this data with anyone outside of the current research group
Related trials for Cognitive Enhancement
Recruiting
The Efficacy of an IADL-based Non-immersive Virtual Reality Training Program to Enhance ADL Performance and Cognitive Function for Persons at Risk of Dementia
Cognitive Enhancement, Subjective Cognitive Decline (SCD)
Active, not recruiting
Art of Memory for Cognitive Enhancement in the Monza Brain Health Service
Subjective Cognitive Decline (SCD), Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ioannis Delis principal investigator
University of Leeds
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nootropics (ginkgo biloba, nicergoline, piracetam, or others), Perceptual decision-making performance and Electroencephalography in people with Cognitive Enhancement, run by University of Leeds at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Perceptual decision-making performance (time frame: Pre- and post- 60 days of supplementation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06689644, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2024.